Practice updates in treating advanced-stage gastric and gastroesophageal junction cancers

Activity Description / Statement of Need:
In this online, self-learning activity:

Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Systemic therapy is the mainstay of treatment for advanced and metastatic disease. There is a widening number of treatment options for GC and GEJC with approved and investigational agents. This learning activity has therefore been designed to bring HCPs’ knowledge of the rationale behind treatment of GC and GEJC up to date and to enhance their competence and performance in the management of it.

Target Audience:
HCPs including: Medical oncologists, pathologists, physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

Cost: Free

View Offer chevron_right

Details

Activity Description / Statement of Need:
In this online, self-learning activity:

Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Systemic therapy is the mainstay of treatment for advanced and metastatic disease. There is a widening number of treatment options for GC and GEJC with approved and investigational agents. This learning activity has therefore been designed to bring HCPs’ knowledge of the rationale behind treatment of GC and GEJC up to date and to enhance their competence and performance in the management of it.

Target Audience:
HCPs including: Medical oncologists, pathologists, physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.